Curi RMB Capital LLC Sells 54 Shares of Humana Inc. (NYSE:HUM)

Curi RMB Capital LLC trimmed its stake in Humana Inc. (NYSE:HUM) by 2.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,299 shares of the insurance provider’s stock after selling 54 shares during the period. Curi RMB Capital LLC’s holdings in Humana were worth $583,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. FPC Investment Advisory Inc. bought a new stake in shares of Humana during the 4th quarter valued at $27,000. Centricity Wealth Management LLC bought a new stake in Humana during the fourth quarter worth about $30,000. LFA Lugano Financial Advisors SA lifted its holdings in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. OFI Invest Asset Management purchased a new stake in shares of Humana in the fourth quarter worth $33,000. Finally, Atwood & Palmer Inc. raised its position in shares of Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Price Performance

NYSE HUM opened at $246.07 on Tuesday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The stock has a market cap of $29.70 billion, a price-to-earnings ratio of 24.73, a PEG ratio of 2.05 and a beta of 0.62. The company’s 50 day moving average is $265.62 and its two-hundred day moving average is $270.27.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.44%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s payout ratio is currently 35.58%.

Analysts Set New Price Targets

HUM has been the subject of several recent analyst reports. Mizuho lifted their target price on shares of Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a report on Wednesday, April 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Morgan Stanley reduced their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. StockNews.com raised Humana from a “hold” rating to a “buy” rating in a report on Monday, April 7th. Finally, JPMorgan Chase & Co. dropped their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Seventeen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus target price of $284.90.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.